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ABSTRACT: Molecular recognition is a highly interdependent process.
Subsite couplings within the active site of proteases are most often revealed
through conditional amino acid preferences in substrate recognition.
However, the potential eﬀect of these couplings on inhibition and thus
inhibitor design is largely unexplored. The present study examines the
interdependency of subsites in HIV-1 protease using a focused library of
protease inhibitors, to aid in future inhibitor design. Previously a series of
darunavir (DRV) analogs was designed to systematically probe the S1′ and
S2′ subsites. Co-crystal structures of these analogs with HIV-1 protease
provide the ideal opportunity to probe subsite interdependency. All-atom
molecular dynamics simulations starting from these structures were
performed and systematically analyzed in terms of atomic ﬂuctuations,
intermolecular interactions, and water structure. These analyses reveal that
the S1′ subsite highly inﬂuences other subsites: the extension of the
hydrophobic P1′ moiety results in 1) reduced van der Waals contacts in the P2′ subsite, 2) more variability in the hydrogen bond
frequencies with catalytic residues and the ﬂap water, and 3) changes in the occupancy of conserved water sites both proximal
and distal to the active site. In addition, one of the monomers in this homodimeric enzyme has atomic ﬂuctuations more highly
correlated with DRV than the other monomer. These relationships intricately link the HIV-1 protease subsites and are critical to
understanding molecular recognition and inhibitor binding. More broadly, the interdependency of subsite recognition within an
active site requires consideration in the selection of chemical moieties in drug design; this strategy is in contrast to what is
traditionally done with independent optimization of chemical moieties of an inhibitor.
■ INTRODUCTION
Human immunodeﬁciency virus type 1 (HIV-1) protease is a
retroviral aspartyl protease that is an essential enzyme required
for processing viral polyproteins and maturation of the virus
and therefore a key therapeutic target. Highly active
antiretroviral therapy (HAART), the current treatment stand-
ard, has signiﬁcantly improved mortality and morbidity rates of
patients infected with HIV-1.1−5 HAART is a combination
therapy consisting of three or more drugs from two or more
classes. Protease inhibitors (PIs) have become a vital
component of HAART and key to treatment of HIV-1
infections. The emergence of resistant viruses threatens the
eﬃcacy of current PIs and can lead to treatment failure.
Currently, there are eight FDA approved PIs. Darunavir
(DRV), the latest PI approved by the FDA, is the most potent
antiretroviral drug thanks to a high antiviral activity and high
genetic barrier to the development of resistance (https://www.
fda.gov/). Multiple mutations throughout the protease are
needed to confer signiﬁcant levels of resistance to DRV.
Understanding the driving forces underlying the superior
resistance proﬁle of DRV compared to other PIs not only
aids the future design of PIs but also due to the wealth of
structural information HIV-1 protease is an excellent system to
test general design principles that can be applied to other
systems.
HIV-1 protease is a 99 amino acid homodimer (Figure 1A).
The active site of HIV-1 protease can be characterized as a
channel that has eight subsites (S4−S1 and S1−S4′). Each
subsite position corresponds to an amino acid of the substrate
(P4−P1 and P1′−P4′ from N to C terminus) with the scissile
bond between the P1−P1′ positions.6 DRV occupies four
subsites (S2 to S2′), with P2, P1, P1′, and P2′, making contacts
with hydrophobic residues and several aspartic acid residues
including catalytic D25 and D25′ (Figure 1B). Because
protease contains two identical monomers, by convention the
monomer binding the C terminal side of substrates and
containing subsites S1′ to S4′ is referred to as the prime
monomer. The aniline moiety of DRV by analogy of
peptidomimetics corresponds to P2′, while the bis-THC moiety
is assigned to P2 (Figure 1B).
The substrate envelope hypothesis has been shown to be an
eﬀective strategy to explain the molecular mechanism of drug
resistance mutations and guide the design of new resistance-
proof inhibitors.7−14 Where inhibitors exceed the substrate
envelope are probable sites for resistance mutations to occur,
and inhibitors designed to ﬁt within the volume that the
endogenous substrates occupy are less prone to resistance.15−18
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DRV has been evaluated against the substrate envelope and ﬁts
well within this constrained volume.12−14 Previous studies
found that the isopropyl functional group at the P1′ position of
DRV did not fully ﬁll the substrate envelope, and thus larger
P1′ moieties could be explored.12 Further, free energy
decomposition studies of HIV-1 protease mutants bound to
DRV showed that replacement of the isopropyl (P1′) and
aniline (P2′) groups could improve potency and the resistance
proﬁle.19,20 Resistance mutations V82A and I84V increase the
size of the active site because the substituted amino acids are
smaller in size, and in response the P1′ and P2′ groups adopt
an alternate conformation that leads to a loss of van der Waals
contacts.
A series of DRV analogs was designed to optimize the DRV
scaﬀold by altering the functional groups at the P1′ and P2′
positions while maintaining the constraints of the substrate
envelope (Table 1). Two functional groups, methyl-butyl and
ethyl-butyl, were evaluated at the P1′ position with ﬁve
diﬀerent moieties at the P2′ position for a total of ten DRV
analogs. Structure, enzymatic activity, antiviral activity, and
pharmacokinetic properties of these inhibitors were evaluated
with wild-type protease and resistant variants.13 All inhibitors,
like DRV, have low picomolar enzymatic potency and antiviral
activity superior to DRV, and several inhibitors also exhibited
good microsomal stability. Additionally, high-resolution X-ray
crystal structures of the DRV series bound to wild-type HIV-1
protease have been determined, and the inhibitors were found
to ﬁt well within the substrate envelope as designed. Previous
design and characterization of these DRV analogs (Table 1)
provide a unique opportunity to determine the coupled subsite
relationships within the active site of HIV-1 protease in
molecular recognition and inhibition.
There are numerous examples where protease subsites
exhibit an interdependence in substrate speciﬁcity, i.e. subsites
cannot be decoupled but must be optimized in a concerted
fashion.21−27 The interdependence of substrate speciﬁcity of
subtilisin, a serine protease,22,24 has been previously analyzed.
Contributions to kcat/Km from each subsite of subtilisin were
not additive; amino acids in one site shield adverse eﬀects of
less favorable amino acids at other distal positions. In Factor
VIIa, another serine protease, the subsites P3 and P4 were
found to be coupled in terms of substrate speciﬁcity as
nonhomologous amino acid classes were preferred in the P3
subsite depending on the amino acid present in the P4
subsite.23 In the protease elastase, the eﬀects of contact
complementary optimization in the P1 subsite were negated if
Figure 1. A) HIV-1 protease bound to DRV (PDB ID: 1T3R). Protease is a symmetric homodimer (monomers in purple and green) where each
monomer is comprised of 99 amino acids but binds asymmetric substrates and inhibitors. By convention the residues and subsites within the
monomer that binds the C-terminal side of peptide substrates or the aniline moiety of DRV are referred to as the prime residues to distinguish
between the identical monomers. B) Chemical structure of DRV with P2 to P1 and P1′ to P2′ moieties labeled. Subsites S2 to S2′ correspond to the
residues that make up the binding cleft for each ligand moiety P2 to P2′ (indicated by purple and light green as in panel A). HIV-1 protease active
site residues that interact with DRV are depicted in green for hydrophobic, red for acidic, and gray for glycine.
Table 1. DRV and 10 Analogs Designed To Optimally Fill
the Substrate Envelope and Evaluated in This Studya
aThe two series, UMASS1−5 and UMASS6−10, have the same R1
group at the P1′ position, and 5 congeneric pairs within the series have
the same R2 group at the P2′ position.
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the contacts in the P4 subsite were optimized independ-
ently.25−27 Each of these examples, as well as many others,
focuses on modifying or optimizing substrate speciﬁcity or
processing. While the interdependence of substrate speciﬁcity is
well-known, these relationships do not necessarily translate to
design and optimization of resistance-proof inhibitors. Little has
been done to evaluate interdependence of subsites in inhibitor
binding. One example in HIV-1 protease showed a
compensatory eﬀect between the P1−P2 and P1′−P2′ subsites
in the evolution of resistance mutations against known PIs.28
In the current study, we aimed to determine if there is an
interdependence between subsites of HIV-1 protease in
inhibitor binding, using the focused library of DRV analogs
where the functional groups at P1′ and P2′ positions are
systematically altered (Table 1). The DRV analogs, along with
the available high-resolution structural data, provided an ideal
set for evaluation of subsite interdependence. Molecular
Dynamics (MD) simulations starting from cocrystallized
structures were performed to systemically analyze the atomic
ﬂuctuations, energetics, hydrophobic and electrostatic inter-
actions, and water structure for HIV-1 protease bound to DRV
and 10 DRV analogs and determine how diﬀerent functional
groups inﬂuence these properties. The inhibitor interactions at
the P1′ position were found to inﬂuence the van der Waals
(vdW) contacts in the P2′ position, as well as hydrogen
bonding between the inhibitor and key structural features,
namely the catalytic residue D25 and the highly conserved ﬂap
water. Thus, subsites in diﬀerential recognition of inhibitors
within the active site of HIV-1 protease are highly coupled and
interdependent.
■ RESULTS
MD trajectories starting from high-resolution structures of
HIV-1 protease cocrystallized with DRV and DRV analogs were
generated and analyzed to reveal subsite interdependence and
interactions between the inhibitor and protein. Each complex
was simulated in triplicate for 100 ns each. Correlated
ﬂuctuations between the protein and inhibitor, vdW contact
energies, electrostatic interactions, and water structure were
evaluated and compared between DRV and the analogs to
reveal subsite relationships.
Asymmetric Inhibitors Propagate Asymmetric Fluc-
tuations Throughout the Enzyme. The asymmetry in B-
factors between the monomers in the crystal structures of the
inhibitor complexes indicated a link between the chemical
moieties present in the substrate binding sites and the dynamics
of the monomer (Figure S1 and analysis in the Supporting
Information: Crystallographic B-factor comparison). To identify
the regions of the homodimeric HIV-1 protease that ﬂuctuate
the most highly in concert with atomic ﬂuctuations of the
bound inhibitor cross-correlational analysis was used. Speciﬁc
regions of the protease are highly correlated/anticorrelated with
the atomic ﬂuctuations of DRV (Figure 2) and DRV analogs
(Figures S2 and S3). Residues D25, T26, G27, G28, D29, G49,
and I50 of the protease were the most correlated with the
ﬂuctuations of the inhibitor, but the correlations of each
monomer with the inhibitors were asymmetric. The nonprime
monomer containing the P2 pocket was always more highly
correlated with the inhibitor motions (Figure 2B, red and
orange colors), while the elbow region in the prime monomer
was the most anticorrelated with the inhibitor (Figure 2B,
blue). Distance diﬀerence plots also showed diﬀerential results
for the two monomers as a result of the asymmetry of the
inhibitor, conﬁrming the results obtained from analysis of the
crystal structures (analysis in the Supporting Information:
Distance dif ference matrices show asymmetric inhibitors impact
homodimeric protease monomers dif ferentially and Figures S4−
S7). Thus, the eﬀects of the asymmetric inhibitor are
propagated in an asymmetric manner to distal protein residues.
Alterations of P1′ Impact P2′ van der Waals Contacts
but Not Vice Versa. The interdependency of subsites was
investigated by evaluating how diﬀerent functional groups at
P1′ and P2′ positions of the inhibitor alter vdW contacts across
subsites. By comparing DRV with UMASS1 and UMASS6,
where the P1′ increases in size by one and then two methyl
groups relative to DRV, respectively (Figure 3), the
interdependency between S1′ and the other subsites was
evaluated. As the P1′ moiety increased in size, vdW contacts at
the S1′ subsite became more favorable as expected, but while
no change was observed at the S1 or S2 subsites, the
corresponding contacts at S2′ became less favorable due to
loss of vdW contacts (Figure 3).
Speciﬁcally, with the addition of each carbon atom, extending
the P1′ moiety, as more favorable contacts with L23, I84, V82,
and I50′ were made (see Figure 4A) the vdW contacts
decreased at P2′. These coupled changes occurred as the
dihedral angle between the P1′ and P2′ moieties was altered,
leading to less favorable contacts between the aniline group of
the inhibitor and protease residues A28′, D29′, and D30′
(Figure 4B). This trend persisted when other congeneric pairs
Figure 2. A) Pearson cross-correlations between DRV inhibitor atoms and C-alpha positions of HIV-1 protease residues. B) Average cross-
correlation intensities by residue determined in panel A mapped onto the protease structure.
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of DRV analogs with the same P2′ moiety were compared
(Figure S8).
Upon binding, the conformational entropy of the inhibitor
decreases as the inhibitor’s degrees of freedom are reduced. An
additional penalty will be paid if the inhibitor’s bound state
deviates from the low energy unbound state. MD simulations of
the free (unbound) inhibitors were run to compare the P1′-P2′
torsion angle of DRV and DRV analogs in the bound and
unbound states. The torsion angle for DRV was the same in
both the bound and unbound states, while there was a 2 to 18
degree perturbation between the bound and unbound states for
all other DRV analogs (Table 2). The hydrophobic extension of
the P1′ moiety not only leads to less favorable vdW contact
energy at the S2′ subsite but the torsion angle between the P1′
and P2′ moieties in the bound state deviates from the lowest
energy state.
Next, the analogs within the two series, which have the same
P1′ but a diﬀering P2′ moiety, were compared. In the P1′
methyl-butyl (UMASS 1−5) and ethyl-butyl (UMASS 6−10)
series, as the chemical diversity was introduced at the P2′
position there was no signiﬁcant change in the vdW contacts
between the protein and inhibitor P1, P2, or P1′ positions
(Figure 5). Therefore, the observation that the P1′ moiety
impacting the vdW contacts at the P2′ position is unidirec-
tional, as the reverse is not true.
Alterations in P1′ Also Impact Key Direct and Water
Mediated Hydrogen Bonds. All intermolecular hydrogen
bonds between DRV and HIV-1 protease were determined
along with the percentage of the time the bond existed during
the MD simulations (Figure S9). Direct protein-inhibitor
hydrogen bonds were observed between DRV and residues
D25, D29, D30, D25′, and D30′. Additionally, there were
water-mediated hydrogen bonds with I50, I50′, and D29′. The
hydrogen bonding patterns between protease and DRV were
compared to other DRV analogs to analyze the eﬀect of
diﬀerent chemical moieties in the S1′ and S2′ subsites.
The two series with diﬀering P1′ (UMASS1−5, UMASS 6−
10) were compared to evaluate the impact of the hydrophobic
extension of the P1′ moiety on the hydrogen bonding patterns
and frequencies in each subsite (Table S1). No signiﬁcant
diﬀerences were observed in the hydrogen bonds of S2 or S1′
subsite with the P1′ extension. For all P2′ congeneric pairs,
with the exception of DRV, UMASS1 and UMASS6, there was
also no dependency between the S1′ and S2′ subsites
(Expanded analysis in the Supporting Information: Interde-
pendency of electrostatic interactions between the S1′ and S2′
subsites mediated by P2′ moiety). Speciﬁcally, the frequency of
the transition state hydrogen bond between the protonated
catalytic residue D25 and the oxygen occupying the P1 position
of the inhibitor (Figure 6A) is more stable when a methyl-butyl
moiety is in the P1′ position regardless of the P2′ moiety. The
P1 hydrogen bond frequencies diﬀered by 14% across the
methyl-butyl series and by 39% across the ethyl-butyl series
(Figure 6B). Thus, the P1′ extension introduced variability in
the frequency of the P1 hydrogen bond, suggesting a
Figure 3. van der Waals contact energies for DRV, UMASS1, and
UMASS6, with the same P2′ moiety but diﬀering hydrophobic
substitutions at P1′. Error bars indicate errors determined by block
averaging over the concatenated three trajectories.
Figure 4. Overlay of the HIV-1 protease structure in complex with DRV, UMASS1, and UMASS6. A) van der Waals contacts (L23, P81, V82, I84,
and I50′) with the P1′ moiety increase, and B) the dihedral angle (cyan circles) between the P1′ and P2′ groups shifts with a hydrophobic extension
of the P1′ moiety, changing the contacts between inhibitor and residues A28′, D29′, and D30′.
Table 2. Comparison of the Dihedral Angle of the P2′
Moiety in the Bound and Unbound States for DRV and DRV
Analogs
P2′ torsion (degrees)
compound bound unbound Δ torsion
DRV −85 −85 0
UMASS1 −81 −90 9
UMASS2 −85 −74 11
UMASS3 −79 −81 2
UMASS4 −84 −92 8
UMASS5 −87 −75 12
UMASS6 −75 −93 18
UMASS7 −75 −81 6
UMASS8 −68 −81 13
UMASS9 −84 −80 4
UMASS10 −84 −69 15
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dependency between the S1 and S1′ subsites. This P1−P1′
dependency indicates that a hydrophobic P1′ extension reduces
the electrostatic interactions in the adjacent P1 subsite.
Within each series (UMASS1−5, UMASS6−10) the impact
of the P2′ position on other subsites was evaluated. The same
hydrogen bonding patterns were observed for UMASS1
through UMASS5 and UMASS6 through UMASS10 within
the S2, S1, and S1′ subsites but not the S2′. The P2′ capping
group inﬂuenced the hydrogen bonding patterns and
frequencies between the P2′ moiety and the S2′ subsite
residues. Namely, the P2′ hydroxyl capping group of UMASS3
and UMASS8 interacted diﬀerently with D29′ and D30′
compared to other DRV analogs, forming three hydrogen
bonds. The heteroatoms of the fused ring system of UMASS4,
UMASS5, UMASS9, and UMASS10 formed only one hydrogen
bond in the S2′ subsite, while UMASS2 and UMASS7, with a
terminal methoxy, formed that same hydrogen bond but at a
much lower frequency (19% and 14%, respectively). While the
chemical functionality of the P2′ moiety greatly inﬂuenced the
hydrogen bonding pattern within the S2′ subsite itself, there
was little eﬀect on other subsites.
Water-mediated hydrogen bond patterns and frequencies
between the inhibitors and the protease were also examined.
Inhibitors with a polar heteroatom in the para position at the
P2′ position (DRV, UMASS1, UMASS3, UMASS6, and
UMASS8) formed a hydrogen bond with D29′. This water
mediated D29′ hydrogen bond is within the S2′ subsite and not
unexpected since the P2′ moiety of these inhibitors is capable
Figure 5. van der Waals contact energies by subsite between DRV analogs and HIV-1 protease. Error bars are the errors determined by block
averaging over the concatenated three trajectories.
Figure 6. A) The hydrogen bond between the inhibitor and D25. B) The change in the frequency of the hydrogen bond shown in panel A for each
congeneric pair. C) Water mediated hydrogen bond between the inhibitor P2′ moiety and I50′. D) The change in frequency of the water mediated
hydrogen bond shown in panel C for each congeneric pair. Frequencies are the sum of two ﬂap water mediated hydrogen bonds with I50′ and the
inhibitor.
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of hydrogen bonding. As expected, the tetra-coordinated ﬂap
water was observed for DRV (Figure S4) and all DRV analogs
with high frequency (Table S2). This ﬂap water is known to
play a critical role in molecular recognition by HIV-1 protease.
While the ﬂap water mediated hydrogen bonding patterns were
similar in the S1 and S1′ subsites across all UMASS analogs, the
frequency of the hydrogen bond with I50′ (Figure 6C) was
more variable within the ethyl-butyl series than the methyl-
butyl series: 61% versus 17% change, respectively (Figure 6D).
The variability in the hydrogen bonding frequency of the ﬂap
water suggests a dependency between the P2′ moiety and the
water mediated hydrogen bond of the P1′ moiety with I50′.
To summarize, the evaluation of intermolecular hydrogen
bonding interactions shows an interdependency between the
P1′ position and hydrogen bonds in the S1 subsite. Speciﬁcally,
extending the P1′ moiety led to a reduction in the frequency of
hydrogen bonding with the catalytic D25. Further, ﬂap water
mediated hydrogen bonding was impacted by introducing
chemical diversity in the S2′ subsite, depending on the P1′
moiety. Thus, key protease−inhibitor interactions are in-
timately linked to the chemical moiety in the S1′ subsite.
The P1′ Moiety Impacts the Surrounding Water
Structure. Water structure is often ignored when evaluating
molecular recognition and binding events. The congeners DRV,
UMASS1, and UMASS6 provide an opportunity to investigate
the impact of increasing hydrophobicity at the P1′ position on
the structured water molecules around the protein-inhibitor
complex. To elucidate the changes in the solvent surrounding
the active site in response to variations in the P1′ moiety, the
explicit water in the MD simulations for DRV, UMASS1, and
UMASS6 was compared. The crystal structures of HIV-1
protease in complex with these three inhibitors were previously
determined to 1.2, 1.95, and 1.5 Å resolution, respectively,13
and showed signiﬁcant variability in water content, rendering
the analysis of the crystallographic waters unfeasible. The
location and mobility of water molecules were evaluated in
terms of occupancy and conservation of water sites during the
simulations, and alterations in water sites were examined across
the three inhibitors. While the number of water molecules in
the proximity of the HIV-1 protease active site varied
signiﬁcantly across inhibitors, water sites with high occupancy
were conserved in the crystal structures (Figure S10).
All water sites within 6 Å of the inhibitor were determined. A
water site was deﬁned as having at least twice the density of
bulk water for the duration of the MD trajectories (see
Materials and Methods for further details). For DRV, UMASS1,
and UMASS6, 31, 33, and 32 water sites were identiﬁed,
respectively. Twenty-seven sites were conserved between at
least two of the inhibitor complexes. On average, all conserved
water sites were occupied at least 50% of the time (Figure 7A).
Water sites 4, 19, 23, and 25 had the highest variability in
occupancy (Figure 7B); two of these water sites are within the
Figure 7. A) The occupancy of the 27 conserved water sites as determined over a 300 ns MD simulation of HIV-1 protease bound to DRV,
UMASS1, and UMASS6. B) The standard deviation in occupancy of each water site shown in panel A. Sites 4, 19, 23, and 25 (ordered by highest
occupancy) have the largest deviation in occupancy for the series DRV, UMASS1, and UMASS6, suggesting that these water sites are inﬂuenced by
the P1′ moiety. C) Water sites with the largest standard deviations are either in direct contact with the ligand (sites 4 and 25) or at distal sites (sites
19 and 23). The DRV-bound HIV-1 protease structure (PDB ID: 1T3R) is displayed to orient the reader to the relative location of conserved water
sites.
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active site, and two are adjacent to the active site (Figure 7C).
For the congeners DRV, UMASS1, and UMASS6, 10 unique
water sites were found (i.e., no equivalent was found in any
other simulation). As observed with the conserved water sites,
these unique sites were located both proximal and distal to the
active site. This result suggests that not only do the changes in
the P1′ position impact water sites directly contacting the active
site but also the eﬀect propagates to distal sites as well. Thus,
the P1′ extension impacted the occupancy of the water sites
both within and distal to the active site.
■ DISCUSSION
While subsite couplings in substrate speciﬁcity have been well
documented for various proteases, an understanding of how
these interdependencies may translate to inhibitor binding has
been lacking. Many active site couplings are not revealed from
static structures. Because protein ﬂexibility and conformational
change are critical to understanding the binding mechanism of
HIV-1 protease, MD simulations of a focused library of DRV
and analogs bound to protease were performed and system-
atically analyzed to reveal the eﬀect of P1′ and P2′ groups on
the interactions of moieties in the other subsites. Two major
ﬁndings from these analyses are that (1) the P1′ moiety at the
S1′ subsite has extensive eﬀects on other subsites and (2)
asymmetry of the inhibitor impacts each monomer diﬀerently.
The S1′ subsite plays a central role, propagating changes to
other subsites (Figure 8). An increase in hydrophobic contacts
of the P1′ moiety decreased contacts in the S2′ subsite, but the
dependency was unidirectional. The P1′ moiety also impacted
the frequency of the hydrogen bond between the inhibitor and
catalytic residue D25, the hydrogen bonds mediated by the
conserved ﬂap water, and the occupancy of water sites both
proximal and distal to the active site. The DRV analogs in the
focused library used were originally designed to increase the
vdW contacts at the S1′ site by extending the P1′ group and
optimally ﬁlling the substrate envelope. However, coupling
between S1′ and S2′ subsites and a reciprocal decrease of
interactions at the S2′ substite indicate these moieties should be
optimized simultaneously, in context with each other.
The asymmetry of the inhibitors was propagated to alter
dynamics throughout the protease, diﬀerentially impacting the
two protease monomers. The most highly concerted atomic
ﬂuctuations between the inhibitors and protease were always in
the 30s and 50s loops of the nonprime monomer, which
interacts more strongly with the inhibitor compared to the
prime monomer. Several of our own previous studies have also
shown that asymmetric inhibitors diﬀerentially aﬀect the two
monomers and disrupt the symmetry of the HIV-1 protease
and the resistance mutations that are present in both
monomers.29 MD simulations of wild-type and a drug resistant
variant of HIV-1 protease bound to DRV revealed one side of
the active site widening while the other side constricting. A
common mechanism of drug resistance for HIV-1 protease may
be through altered protein dynamics, shifting the ensemble and
altering the ﬂexibility of the enzyme.30,31 In addition, mutations
distal from the active site were found to asymmetrically disrupt
the hydrogen-bonding network, which propagated changes
through the two monomers diﬀerently to the active site.
The ﬁndings in this work are consistent with previous studies
that found structural couplings between the P1−P2 and P1′−
P2′ subsites28 when optimizing amino acids at these positions
for peptide-based inhibitor design. The current work extended
the analysis to the whole inhibitor-protease-solvent system, as
well as determining the underlying molecular mechanisms, and
intermolecular interactions and energetics behind subsite
couplings. Since previous studies revealed that altering the
P1′ and P2′ moieties could improve inhibitor properties,19 the
focus was on the corresponding subsites. Future studies could
include systematic evaluation of other subsites, diﬀerent
inhibitor pharmacophores, and extend to drug resistant variants
to understand how/if subsite interdependency is altered.
The ability to design robust and potent therapeutics is
limited by our understanding of mechanisms of inhibition.
While subsite interdependency has been investigated by means
of substrate optimization, little had been done on inhibitor
binding. Elucidation of the couplings between the subsites of
HIV-1 protease in binding of inhibitors not only will aid in
future drug design but also will provide a proof of concept for
application to other therapeutic targets. We have shown that
the HIV-1 protease active site is comprised of many highly
interdependent relationships that cannot be further decon-
structed. These relationships can be used to guide the design of
new inhibitors and provide a template to elucidate subsite
interdependencies for other important therapeutic targets.
■ MATERIALS AND METHODS
Protein Structure Preparation. Crystallographic struc-
tures of DRV and DRV analogs bound to HIV-1 protease were
previously determined (PDB ID: 1T3R, 3O99, 3O9A, 3O9B,
3O9C, 3O9D, 3O9E, 3O9F, 3O9G, 3O9H, 3O9I).13 All
structures were prepared for simulation using the Protein
Preparation Wizard from Schrödinger;32,33 hydrogen atoms
were added, multiple residue conformations were resolved,
protonation states were determined, and any structural
violations were resolved. All crystallographic waters were
maintained, but crystallization buﬀers and salts were removed.
The hydrogen bond network was optimized by exhaustive
sampling of water orientations and ﬂipping the side chain
orientation of Asn, Gln, His, and terminal hydroxyl and thiol
hydrogen as appropriate. The structures were minimized with
heavy atoms restraints until an RMSD of 0.3 Å was achieved
using the OPLS2005 force ﬁeld (which was also used to
parametrize the inhibitors).34−36
Molecular Dynamics Simulations. All MD simulations of
the HIV-1 protease bound complex and free inhibitor were
performed using Desmond36−39 as implemented by Schrö-
dinger using the OPLS2005 force ﬁeld. Systems were prepared
by solvating the structure in a cubic box that extended at least
Figure 8. Interdependencies between subsites mapped onto the DRV
structure.
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10 Å beyond the nearest solute atom in all directions using the
TIP3 solvation model.40 Sodium chloride was added to the
equivalent of 150 mM to simulate physiological conditions. The
system was neutralized by adding counterions as needed (Na+
or Cl−).
A rigorous pre-equilibration model was employed as
described elsewhere.41 Brieﬂy, a series of restrained minimiza-
tion were performed to gradually relax the system. Initially all
heavy solute atoms were restrained with a force constant of
1000 kcal mol−1 Å−2 for 10 steps with steepest descent followed
by up to 2000 steps using the LBFG method to a convergence
of 50 kcal mol−1 Å−2. Restraints were removed from side chains
using LBFG for 5000 steps or until a convergence of 50 kcal
mol−1 Å−2. The restraints on the backbone were gradually
removed in procession using the following force constants
1000, 500, 250, 100, 50, 10, 1, and 0 kcal mol−1 Å−2 using the
LBFG method to a convergence of 50 kcal mol−1 Å−2.
A series of short preproduction MD simulations were
performed to equilibrate the system. A 10 ps NVT ensemble
with restraints on solute heavy atoms of 50 kcal mol−1 Å−2
using a Berendsen thermostat at 10 K was performed. A 1 fs
time step for bonded and short-range interaction up to 9 Å and
a 3 fs time step for long-range electrostatic interactions were
employed. A 10 ps MD simulation using an NPT ensemble
with a Berendsen thermostat followed, run at 10 K with a 2 ps
window for bonded and short-range interactions and 6 fs for
long-range electrostatics. Over 50 ps, the temperature of the
system was increased to 300 K with restraints on heavy solute
atoms followed by a 10 ps simulation where all harmonic
restraints were removed. Production simulations were
performed using an NPT ensemble with a Nose-Hover
thermostat and a Martyna-Tuckerman-Klein (MTK) barostat.
Simulations were carried out with no harmonic restraints for
100 ns at 300 K and 1 bar. The cutoﬀ for nonbonded
interactions was 9 Å using Particle Mesh Ewald (PME)
methodology. All simulations were performed in triplicate to
check for reproducibility and ensure suﬃcient sampling, each
with a diﬀerent initial velocity for a total production time of 300
ns.
van der Waals Contact Analysis. The intermolecular van
der Waals contact potential for each protease-inhibitor complex
was calculated using a modiﬁed Lennard-Jones potential, V(rij),
equivalent to 4ε[(σ/rij)
12 − (σ/rij)6] where r is the distance
between atom pairs i of the protease and j of the inhibitor. The
values of ε and σ are the depth of the energy well and the
diameter of atoms when treated as a hard sphere. All protease-
inhibitor nonbonded pairs within 6 Å were included. When the
distance was less than ε the potential was set to ε.42 The error
associated with van der Waals energies was determined using
block averaging over a total of 300 ns of concatenated
trajectories.
Hydrogen Bonding Analysis. Identiﬁcation and fre-
quency of hydrogen bonds between protease and inhibitor
(direct and water mediated) were determined using an in-house
script built oﬀ of the Schrödinger API.43 A hydrogen bond was
determined to be present if the distance between the hydrogen
and acceptor atoms was less than 2.5 Å. Additionally the
following geometric restraints were required: 1) the angle
between the donor-hydrogen-acceptor atoms had to be at least
120 degrees and 2) the angle between the hydrogen, acceptor,
and atom bonded to the acceptor atom had to be at least 90
degrees. These criteria were applied to each frame of the
trajectories to determine the frequency of the hydrogen bond.
Where multiple hydrogen bonds were observed with a protein
residue, such as with D25′, D29′, I50′, D30, and I50, the
frequencies were added up and treated as a single electrostatic
interaction.
Water Site Analysis. The spatially resolved water density
from MD trajectories was calculated using an in-house Python
script using a grid based approach, similar to one previously
described.44 Modules from the Schrödinger python API were
utilized for trajectory handling and structural alignment. Each
frame of the MD trajectory was ﬁtted on a common reference
frame. Thereafter the coordinates of the water oxygen atoms
within 6 Å of the protein were mapped on a three-dimensional
rectangular grid. The distance between the adjacent grid points
was set to 0.5 Å. The grid spacing represents a compromise
between maintaining good spatial resolution and a relatively
low statistical error.
Following grid generation, local maxima in the discretized
density distribution were identiﬁed. As an initial ﬁlter, only grid
points with an average density of at least twice that of bulk
water (0.066 Å−3) were considered. A grid point qualiﬁed as a
water site if its density exceeded both this initial cutoﬀ value
and the density of all adjacent grid points. Finally, if two or
more local maxima were located within 1.5 Å of each other,
these grid points were considered to contribute to the same
water site, and the coordinates of the water site were calculated
based on the density weighted values of all contributing
maxima.
The water-site occupancy was determined by comparing its
coordinates with the coordinates of the water oxygen atoms in
the prealigned trajectory. If the oxygen atom of a TIP3P water-
molecule was located within 1.5 Å of the water-site, the
molecule was considered to occupy the water site. If at any
point during the course of the simulation more than one water-
molecule was located within 1.5 Å, the water site was still
considered to be occupied by only one water-molecule. For all
subsequent calculations the water-molecule closer to the site
was considered to be the ”occupying” water.
Cross-Correlations. Atomic positional ﬂuctuations were
determined for each simulation, and cross correlations between
atom pairs were calculated using
=
Δ Δ
Δ Δ
R R
R R
COi j
i j
i j
,
2 1/2 2 1/2
where ΔRi is the change in the position of site i, and ΔRi is the
change in the position in site j. The range of the correlation
varies from minus one to one, minus one meaning the atom
pair is completely anticorrelated, one meaning a complete
correlation, and zero meaning that there is no correlation.
Results were generated and plotted using in-house FORTRAN
scripts and MatLab.
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